Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(14):1039; doi:10.1093/jnci/94.14.1039
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Wang, L.
Right arrow Articles by Arnold, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wang, L.
Right arrow Articles by Arnold, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 14, 1039, July 17, 2002
© 2002 Oxford University Press

Press Release

Benefit of Adding Chemotherapy To Tamoxifen for Breast Cancer May Depend on Hormone Receptor Status

Linda Wang, Assistant News Editor, Katherine Arnold, News Editor

jncimedia@oupjournals.org

The first 10% of the full text of this article appears below.

Adjuvant chemotherapy before tamoxifen may improve survival of postmenopausal women with lymph node-negative, estrogen receptor (ER)-negative breast cancers, according to new research in the July 17 issue of the Journal of the National Cancer Institute. However, women with ER-positive breast cancers experienced no improvement from combined therapy with a short course of chemotherapy when compared with tamoxifen alone.

Postmenopausal women with lymph node-negative . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?